Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
SFA Therapeutics logo — A New Paradigm in Drug Development

SFA Therapeutics

A New Paradigm in Drug Development

Founded 2016 United States Jenkintown, United States 9 employees Convertible Note Total: $8.73M Biotechnology, Health Care +1

General Information

Company Name SFA Therapeutics
Founded Year 2016
Location United States Jenkintown, United States +1
Employees 9
Industries Biotechnology, Health Care, Health and Wellness
Funding Stage Convertible Note
Social

Get notified when SFA Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About SFA Therapeutics

SFA Therapeutics is a clinical stage start-up biotech company founded in 2016 with a focus on developing compounds discovered in the human microbiome. Their patented and proprietary platform aims to immuno-modulate inflammatory factors derived from the human gut microbiome. The technology, licensed from and supported by research at Temple University in Philadelphia, positions SFA Therapeutics as a pioneer in native immunotherapy. The company's products are currently undergoing investigations in the areas of cancer, liver, and autoimmune disease, showcasing their potential to address critical health challenges in today's society. In November 2023, SFA Therapeutics successfully secured a significant $4.50M Venture Round investment from notable investors including Asymmetry Ventures, Ben Franklin Technology Partners of Southeastern Pennsylvania, North South Ventures, and Savantus Ventures. This influx of funding not only demonstrates confidence in the company's innovative approach but also provides valuable resources to further their research and development efforts. SFA Therapeutics's dedication to leveraging the human microbiome for drug development signifies a forward-thinking approach within the biotechnology and healthcare industries. As they continue to advance their unique platform, the company holds the potential to make a substantial impact in the treatment of various diseases, offering a promising investment opportunity for venture capitalists seeking to support groundbreaking solutions in the healthcare space.

Taxonomy: biotech, drug development, microbiome, immunotherapy, clinical stage, patented technology, inflammatory disease, autoimmune disease, cancer treatment, liver disease, Temple University, biopharmaceutical, metabolites as drugs, immuno-modulation, startup

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Convertible Note •••••• 4
Investor Investor Investor Investor
09 Nov 2023
Seed Round •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		20 Jun 2022
Seed Round •••••• - 17 Aug 2021
Grant •••••• - 18 Jun 2020

SFA Therapeutics Alternatives & Competitors

SFA Therapeutics vs
OptiBiotix Health Plc
OptiBiotix Health Plc United Kingdom

Better Science, Better Health 🧬 The OptiBiotix difference; improving health and wellbeing.

Post Ipo Equity
13 employees
Biotechnology, Health Care
SFA Therapeutics vs
MedBiome
MedBiome Canada

Targeting the microbiome to improve human health

1 employees
Biotechnology, Pharmaceutical
SFA Therapeutics vs
Jona
Jona United States

Discover Within

Seed
27 employees
AI, Health Care

FAQ About SFA Therapeutics

A New Paradigm in Drug Development
SFA Therapeutics was founded in 2016.
SFA Therapeutics is headquartered in Jenkintown, United States.
SFA Therapeutics operates in the following industries: Biotechnology, Health Care, Health and Wellness.
SFA Therapeutics has approximately 9 employees.
SFA Therapeutics has completed 4 funding rounds, raising a total of $8.73M. The latest funding stage is Convertible Note.
Top alternatives and competitors to SFA Therapeutics include OptiBiotix Health Plc, MedBiome, Jona, EnteroBiotix, CHAIN Biotechnology Ltd. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
SFA Therapeutics and OptiBiotix Health Plc are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors SFA Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy